Xia Peng

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
76 papers · 1,073 citations · H-index 21

PAPERS

Structural Optimization of Next-Generation TRK Inhibitors against Acquired Drug Resistance Mutations for the Treatment of Solid Tumors.
20253 citationsauthor #4
Discovery of Hydrazineyl Amide Derivative of Pseudolaric Acid B for Reprogramming Tumor-Associated Macrophages Against Tumor Growth
20250 citationsauthor #1
13,14-seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation.
20242 citationsauthor #2
Incorporation of a rigid 1,3-diketone-containing fragment led to significantly improved AXL inhibitory activity: design, synthesis, and SAR of the anilinopyrimidine AXL inhibitors
20240 citationsauthor #2
Remodeling tumor‐associated macrophage for anti‐cancer effects by rational design of irreversible inhibition of mitogen‐activated protein kinase‐activated protein kinase 2
20240 citationsauthor #4
Discovery, Optimization, and Evaluation of Novel Pyridin-2(1H)-one Analogues as Potent TRK Inhibitors for Cancer Treatment.
202410 citationsauthor #2
Discovery and optimization of 3‐(indolin‐5‐yloxy)pyridin‐2‐amine derivatives as potent necroptosis inhibitors
20241 citationsauthor #3
Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors
20240 citationsauthor #2
Synthesis and evaluation of hybrid molecules as RIPK1 and HDACs dual inhibitors
20242 citationsauthor #5
Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.
20236 citationsauthor #5
Unprecedented sesterterpenoids, orientanoids A–C: discovery, bioinspired total synthesis and antitumor immunity
20235 citationsauthor #4
Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors
20237 citationsauthor #6
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer
202310 citationsauthor #6
Laeviganoids A-T, ent-Clerodane-Type Diterpenoids from Croton laevigatus.
202312 citationsauthor #4
Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
20231 citationsauthor #2
Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.
20228 citationsauthor #5
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
202214 citationsauthor #5
18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis
20228 citationsauthor #4
Design, synthesis and biological evaluation of 4-aminoquinoline derivatives as receptor-interacting protein kinase 2 (RIPK2) inhibitors
20224 citationsauthor #4
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
202115 citationsauthor #4
The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation
20217 citationsauthor #2
Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.
202145 citationsauthor #3
Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
202111 citationsauthor #2
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
202014 citationsauthor #4
Corrigendum to "SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo" [Cancer Lett. 351 (2014) 143-50].
20200 citationsauthor #5
Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors
202025 citationsauthor #6
SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors
20200 citationsauthor #4
Synthesis of triazolotriazine derivatives as c-Met inhibitors
20204 citationsauthor #2
DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo
20206 citationsauthor #7
Abstract 3051: A potent pyrimidinone Axl inhibitor DW17401
20200 citationsauthor #2
Abstract A78: Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
20200 citationsauthor #14
Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.
201915 citationsauthor #8
Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models
201930 citationsauthor #1
The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
201810 citationsauthor #4
Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles.
201831 citationsauthor #2
Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.
201831 citationsauthor #2
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma
201750 citationsauthor #12
Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models
201728 citationsauthor #3
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
201719 citationsauthor #5
SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models
201716 citationsauthor #3
Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.
20176 citationsauthor #4
Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
201717 citationsauthor #6
Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
201714 citationsauthor #2
Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.
201711 citationsauthor #2
Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors.
201612 citationsauthor #4
Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
201632 citationsauthor #2
Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
201622 citationsauthor #3
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
201633 citationsauthor #6
Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors
201627 citationsauthor #2
Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold.
20168 citationsauthor #2
Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
20168 citationsauthor #4
Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.
201542 citationsauthor #4
Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.
201521 citationsauthor #4
Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
201515 citationsauthor #5
Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.
201534 citationsauthor #5
DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro
20153 citationsauthor #4
Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.
201545 citationsauthor #4
Correction to Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.
20150 citationsauthor #4
Discovery of potent 1H-imidazo[4,5-b]pyridine-based c-Met kinase inhibitors via mechanism-directed structural optimization.
20159 citationsauthor #5
A divergent approach to benzylisoquinoline-type and oxoaporphine alkaloids via regioselective direct ring metalation of alkoxy isoquinolines
20150 citationsauthor #19
Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
201515 citationsauthor #4
Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
201531 citationsauthor #2
Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold
20145 citationsauthor #4
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.
201432 citationsauthor #3
Discovery of novel type II c-Met inhibitors based on BMS-777607.
201423 citationsauthor #4
Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.
201425 citationsauthor #4
SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.
201414 citationsauthor #5
Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
201418 citationsauthor #4
Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.
201314 citationsauthor #4
Abstract B285: A novel, potent, highly selective inhibitor of c-Met kinase, Simm559, inhibits c-Met-dependent neoplastic phenotypes in vitro and in vivo.
20130 citationsauthor #5
Abstract B99: Discovery of 2,4-diarylaminopyrimidine SOMCL-12-81 as a potent inhibitor targeting both wild and mutant ALK kinases.
20131 citationsauthor #4
Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
201312 citationsauthor #4
Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
20136 citationsauthor #5
Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.
201233 citationsauthor #6
Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
201226 citationsauthor #5
Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition
20129 citationsauthor #4

TIMELINE

2012 68 citations

2013 33 citations

2014 117 citations

2015 215 citations

2016 142 citations

2017 161 citations

2018 72 citations

2019 45 citations

2020 49 citations

2021 78 citations

2022 34 citations

2023 41 citations

2024 15 citations

2025 3 citations

COAUTHOR MAP

CONCEPT FOOTPRINT